What is claimed is:

1. A method for detecting LDL and denatured LDL in blood using as a measuring subject a complex of lower density lipoprotein (LDL) or denatured lower density lipoprotein (denatured LDL: containing oxidized LDL) in which LDL is not oxidatively denatured with an acute phase reactant, blood coagulation-fibrinolytic related protein or disinfectant substance produced by macrophage.

2. The method for detecting LDL and denatured LDL according to Claim 1, using as a measuring subject a complex of an accute phase reactant such as α1-antitrypsin, fibrinogen, fibronectin, lipoprotein (a), C-reactive protein (CRP), Serum amyloid A (SAA), Serum amyloid P component (SAP), α2-macroglobulin, α1-antichymotrypsin, α1-acidoglycoprotein, complement component and the like with LDL or denatured LDL.

3. The method for detecting LDL and denatured LDL according to Claim 1, using as a measuring subject a complex of an coagulation-fibrinolytic related protein such as a tissue factor, plasminogen, prothrombin, thrombin, antithrombin 3, plasmin activator inhibitor 1 and the like with LDL or denatured LDL.

4. The method for detecting LDL and denatured LDL according to Claim 1, using as a measuring subject a complex of a disinfectant substance produced by macrophage such as myeloperoxidase, lactoferrin, lysozyme, basic protein and the like with LDL or denatured LDL.

5. The method for detecting LDL and denautred LDL according to Claim 1 using an immunological measuring method such as an enzyme immunoassay, latex flocculation method, immunological emission spectrochemical analysis, immunochromato method and the like.

6. The method for detecting LDL and denautred LDL according to Claim 2 using an immunological measuring method such as an enzyme immunoassay, latex flocculation method, immunological emission spectrochemical analysis, immunochromato method and the like.

7. The method for detecting LDL and denautred LDL according to Claim 3 using an immunological measuring method such as an enzyme immunoassay, latex flocculation method, immunological emission spectrochemical analysis, immunochromato method and the like.

8. The method for detecting LDL and denautred LDL according to Claim 4 using an immunological measuring method such as an enzyme immunoassay, latex flocculation method, immunological emission spectrochemical analysis, immunochromato method and the like.

Subt a2

9. A method for detecting novel lipoprotein concerning arteriosclerotic lesion described in Claim 2 using an antihuman fibrinogen antibody and an immune reaction detecting reagent such as an antihuman ApoB antibody and the like labeled with a labeling substance typically including an enzyme.

10. A method for detecting novel lipoprotein concerning arteriosclerotic lesion described in Claim 2 using an antihuman fibronectin antibody and an immune reaction detecting reagent such as an antihuman ApoB antibody and the like labeled with a labeling substance typically including an enzyme.

11. A monocolonal antibody produced from a hybridoma obtained by fusing a mouse myeloma cell with a spleen cell from mammals immunized with a LDL/fibronectin coomplex, wherein the antibody does not react with native fibronectin and ApoB (native and denatured ApoB) and specifically recognizes a LDL/fibronectin complex.

add
a'